Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.
Microplate method for retrovirus-induced transformation of normal human T-cells.
J Immunol Methods. 1984 Oct 26;73(2):379-85. Unique Identifier : AIDSLINE MED/85031881 Sugamura K; Sakitani M; Hinuma Y
Abstract:
An adult T-cell leukemia virus (ATLV) producer cell line (TL-Su) derived from a healthy ATLV-carrier, was used for virus-induced transformation of normal human T-cells. The transformation was carried out on microplates by co-cultivation of a limiting number of normal peripheral blood leukocytes (PBL) as transformed target cells and 2 X 10(4)/well of TL-Su cells irradiated lethally. The frequency of establishment of transformed cell lines correlated with the dose of PBL. The transforming target cell number was estimated to be approximately one per 500 PBL by the microplate method using TL-Su effector cells. When 1 X 10(3) PBL per well were plated, more than 90% of wells showed immortalizing transformation of PBL. Twenty transformed cell lines obtained from microplates with 500 PBL per well were shown to be of T-cell lineage. Ten of them were defined as belonging to the helper/inducer T-cell subset with Leu 3a antigen, and 4 were demonstrated to be of the cytotoxic/suppressor T-cell subset with Leu 2a antigen. The transformed cells always expressed Tac and OKT9 antigens (considered to be IL2 and transferrin receptors respectively). ATLV antigens were also expressed in all these cell lines tested, but their molecular species detected by radioimmunoprecipitation varied regardless of PBL donors and T-cell subsets. We propose this microplate transformation method as an advantageous system for obtaining abundant T-cell lines and for screening their immunological functions.
Keywords: Antigens, Surface/ANALYSIS Antigens, Viral/ANALYSIS Cell Line *Cell Transformation, Viral Cells, Cultured Human *HTLV-BLV Viruses Molecular Weight Support, Non-U.S. Gov't T-Lymphocytes/IMMUNOLOGY/*MICROBIOLOGY JOURNAL ARTICLE
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1985. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.
